These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 34270785)

  • 21. Combination therapy with clindamycin and rifampicin for hidradenitis suppurativa: a series of 116 consecutive patients.
    Gener G; Canoui-Poitrine F; Revuz JE; Faye O; Poli F; Gabison G; Pouget F; Viallette C; Wolkenstein P; Bastuji-Garin S
    Dermatology; 2009; 219(2):148-54. PubMed ID: 19590173
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clindamycin as unique antibiotic choice in Hidradenitis Suppurativa.
    Rosi E; Pescitelli L; Ricceri F; Di Cesare A; Novelli A; Pimpinelli N; Prignano F
    Dermatol Ther; 2019 Mar; 32(2):e12792. PubMed ID: 30515931
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral clindamycin and rifampicin in the treatment of hidradenitis suppurativa-acne inversa: a prospective study on 23 patients.
    Bettoli V; Zauli S; Borghi A; Toni G; Minghetti S; Ricci M; Virgili A
    J Eur Acad Dermatol Venereol; 2014 Jan; 28(1):125-6. PubMed ID: 23451831
    [No Abstract]   [Full Text] [Related]  

  • 24. KITTEN following CAT on the long-term use of rifampicin in hidradenitis suppurativa and effectiveness of oral contraceptives.
    Yazdanyar S; Jemec GB
    Br J Dermatol; 2019 Jul; 181(1):225-226. PubMed ID: 30907428
    [No Abstract]   [Full Text] [Related]  

  • 25. The effect of combined treatment with oral clindamycin and oral rifampicin in patients with hidradenitis suppurativa.
    van der Zee HH; Boer J; Prens EP; Jemec GB
    Dermatology; 2009; 219(2):143-7. PubMed ID: 19590174
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of hidradenitis suppurativa with rifampicin: have we forgotten tuberculosis?
    Mendes-Bastos P; Macedo R; Duarte R
    Br J Dermatol; 2017 Oct; 177(4):e150-e151. PubMed ID: 28718933
    [No Abstract]   [Full Text] [Related]  

  • 27. Clindamycin alone may be enough. Is it time to abandon rifampicin for hidradenitis suppurativa?
    Caposiena Caro RD; Bianchi L
    Br J Dermatol; 2019 May; 180(5):1262. PubMed ID: 30604861
    [No Abstract]   [Full Text] [Related]  

  • 28. Prolonged clindamycin and rifampicin for hidradenitis suppurativa: resist to prevent resistance.
    Hambly R; Kirby B
    Br J Dermatol; 2019 Apr; 180(4):702-703. PubMed ID: 30933345
    [No Abstract]   [Full Text] [Related]  

  • 29. Clindamycin alone may be enough. Is it time to abandon rifampicin for hidradenitis suppurativa? Reply from the authors.
    Albrecht J; Barbaric J; Nast A
    Br J Dermatol; 2019 May; 180(5):1262-1263. PubMed ID: 30604869
    [No Abstract]   [Full Text] [Related]  

  • 30. The Microbiology of Hidradenitis Suppurativa.
    Ring HC; Emtestam L
    Dermatol Clin; 2016 Jan; 34(1):29-35. PubMed ID: 26617355
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term clinical safety of clindamycin and rifampicin combination for the treatment of hidradenitis suppurativa: a strategy to reduce side-effects, improving patients' compliance.
    Marasca C; Masarà A; Annunziata MC; Bettoli V; Luciano MA; Fabbrocini G
    Br J Dermatol; 2019 Apr; 180(4):949. PubMed ID: 30430549
    [No Abstract]   [Full Text] [Related]  

  • 32. Rifampin and clindamycin are safe long-term: Response to "North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations Part II: Topical, intralesional, and systemic medical management".
    Albrecht J; Bigby M
    J Am Acad Dermatol; 2023 Jan; 88(1):e31. PubMed ID: 31568806
    [No Abstract]   [Full Text] [Related]  

  • 33. Efficacy and safety of topical resorcinol 15% versus topical clindamycin 1% in the management of mild-to-moderate hidradenitis suppurativa: A retrospective study.
    Molinelli E; Brisigotti V; Simonetti O; Sapigni C; D'Agostino GM; Rizzetto G; Giacchetti A; Offidani A
    Dermatol Ther; 2022 Jun; 35(6):e15439. PubMed ID: 35278025
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa.
    Jemec GB; Wendelboe P
    J Am Acad Dermatol; 1998 Dec; 39(6):971-4. PubMed ID: 9843011
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibiotic Treatment of Hidradenitis Suppurativa.
    Bettoli V; Join-Lambert O; Nassif A
    Dermatol Clin; 2016 Jan; 34(1):81-9. PubMed ID: 26617361
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nanostructured lipid carriers for hair follicle-targeted delivery of clindamycin and rifampicin to hidradenitis suppurativa treatment.
    Pereira MN; Tolentino S; Pires FQ; Anjos JLV; Alonso A; Gratieri T; Cunha-Filho M; Gelfuso GM
    Colloids Surf B Biointerfaces; 2021 Jan; 197():111448. PubMed ID: 33181388
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An Update on Medical Treatment Options for Hidradenitis Suppurativa.
    Deckers IE; Prens EP
    Drugs; 2016 Feb; 76(2):215-29. PubMed ID: 26659474
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hidradenitis Suppurativa: Rapid Evidence Review.
    Wipperman J; Bragg DA; Litzner B
    Am Fam Physician; 2019 Nov; 100(9):562-569. PubMed ID: 31674740
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An oral supplementation based on myo-inositol, folic acid and liposomal magnesium may act synergistically with antibiotic therapy and can improve metabolic profile in patients affected by Hidradenitis suppurativa: our experience.
    Donnarumma M; Marasca C; Palma M; Vastarella M; Annunziata MC; Fabbrocini G
    G Ital Dermatol Venereol; 2020 Dec; 155(6):749-753. PubMed ID: 30249083
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Acne inversa (hidradenitis suppurativa)].
    Iesalnieks I; Dornseifer U
    Chirurg; 2020 Apr; 91(4):293-300. PubMed ID: 31915870
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.